Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.
Following the success of 3 clinical trials, the US Food and Drug Administration granted approval to a once-monthly, self-injectable preventive treatment for adults with migraine.
